Replies to post #775262 on NorthWest Biotherapeutics Inc (NWBO)

[Slave1]

Just to clarify for anyone reading, the method licensed by NWBO from Roswell isn’t just about using dendritic cells with lysate. It’s specifically designed to activate T cells that can recognize not only tumor cells but also the blood vessels and support structures feeding the tumor. That vascular targeting effect, achieved through broad antigen exposure from pooled lysate, is a key part of what makes the platform unique.

Also worth noting, those Mayo trials were funded only by the Ivy Foundation and conducted through Mayo Clinic. No Merck, no NIH, no NCI, and no pharma involvement. That’s important. It kept the platform development independent, under the radar, and unencumbered by outside ownership. Ivy also later funded Dr. Liau’s DCVax work at UCLA. Looking back, it’s clear they were backing the method itself, not any one institution. Now that same method sits under NWBO’s exclusive license.

[Chiugray]

Slave1, That is really good insight, pulling many things together. Very sharp of you. So the Mayo clinic DC trials are covered by NWBO patents, and therefore the Mill Creek Life Sciences IP is as well.

This is becoming more and more apparent that NWBO's IP and moat for DC therapy holds a dominant position. Novel treatment discoveries and strategies may come to realize
- their medicine can be greatly enhanced with DCVax, and/or
- if they work with DCs, realize that their commercial path leads to licensing rights with NWBO.

[eagle8]

Thank you Slave 1 for this explanation.
And thank you for all your informative posts.

GLTU

[exwannabe]

Use of allogenic lysates for DC vaccines has been trialed for over 20 years now. Here are some results published in 2009

Hust because you guys found something you did not know does not make it anything new.

And just like the autologous lysate version, nobody owns the tech as the core patents all expired.

[MarauderWarlock33]

What a relief - second thought we got a stiff competition right around the corner. Thank's for the clarification. My steps got bit lighter. LOL

[beartrap12]

Slave1, I believe your post here answers the questions I had from yesterday that I was going to PM you about. But now that it was brought up by others, I'll explore it a little more here in the open. That question: "Is Merck trying to side-step us by using trials with Roswell Park and Mayo Clinic that seem to mimic what we own?"

Yesterday, among other perplexing comments, you wrote in reference to Mayo/Roswell pooled tumor lysate trials with Merck:

The product in question might not be separate at all (from our DCVax products). It may be the same architecture, the same immune engine, just stripped of its autologous tumor input. Who is behind it has not been named, (NWB?) but the blueprint is unmistakable.

Then you went on to write about the Merck trials:

Several trials sponsored by Roswell Park or Kalinski’s lab have combined dendritic cell vaccines with checkpoint inhibitors like pembrolizumab. These include studies in colorectal cancer, head and neck cancer, and solid tumors, with Merck often providing drug or in-kind support. The protocols are structurally similar to DCVax-Direct, using antigen loaded dendritic cells matured under Kalinski’s patented cytokine conditions. That intellectual property belongs to Roswell Park and remains exclusively licensed to Northwest Biotherapeutics.

Then today you said unequivocally:

The company (NWBO) holds the rights to a specific method combining pooled tumor lysate with autologous dendritic cells to induce immune responses against solid tumors. That is the approach Mayo studied, Mill Creek manufactured, and NWBO controls under its license.

Taken together, the data, funding, and regulatory position suggest that while development occurred across institutions, the underlying platform method remains within NWBO’s IP framework.

So, my final question is: If it's true that Merck is testing it's Keytruda with NWBO's in-licenced DC products from Roswell, are they plotting to get ahead of us or planning to partner with us? I'm not actually asking you to make a wild guess, so much as an educated one, based on the facts.
Thanks, Slave1! Have a great weekend!